176 related articles for article (PubMed ID: 11646977)
1. AIDS study casts doubt on value of hastened drug approval in U.S.
Altman LK
N Y Times Web; 1993 Apr; ():C3. PubMed ID: 11646977
[No Abstract] [Full Text] [Related]
2. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures.
Dunbar MM
Food Drug Cosmet Law J; 1991 Sep; 46(5):673-706. PubMed ID: 11651380
[No Abstract] [Full Text] [Related]
3. Protectionism and the new research imperative in pediatric AIDS.
Ackerman TF
IRB; 1990; 12(5):1-5. PubMed ID: 11654001
[No Abstract] [Full Text] [Related]
4. Trial of experimental AIDS drug to be continued, with revisions.
Kolata G
N Y Times Web; 1990 Mar; ():A1, A15. PubMed ID: 11646750
[No Abstract] [Full Text] [Related]
5. The FDA's response to AIDS: paradigm shift in new drug policy?
Podraza R
Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267
[No Abstract] [Full Text] [Related]
6. Faith (healing), hope and charity at the FDA: the politics of AIDS drug trials.
Annas GJ
Villanova Law Rev; 1989 Sep; 34(5):771-97. PubMed ID: 11651162
[No Abstract] [Full Text] [Related]
7. Placebo use is suspended in overseas AIDS trials.
Stolberg SG
N Y Times Web; 1998 Feb; ():A16. PubMed ID: 11647550
[No Abstract] [Full Text] [Related]
8. Twice wrong on AIDS.
Gieringer D
N Y Times Web; 1987 Jan; ():A21. PubMed ID: 11646161
[No Abstract] [Full Text] [Related]
9. Considering experimentation and elusive truth: informed consent made difficult.
Brodeur D
Issues (St Louis Mo); 1992; 7(2):1-8. PubMed ID: 11659444
[No Abstract] [Full Text] [Related]
10. The need for improved access to experimental drug therapy: AIDS activists and their call for a parallel track policy.
Terrizzi L
Adm Law J; 1991; 4(3):589-634. PubMed ID: 11659598
[No Abstract] [Full Text] [Related]
11. Regulation of drug treatments for HIV and AIDS: a contractarian model of access.
Salbu SR
Yale J Regul; 1994; 11(2):401-53. PubMed ID: 11660141
[No Abstract] [Full Text] [Related]
12. Women and HIV/AIDS research: the barriers to equity.
Levine C
IRB; 1991; 13(1-2):18-22. PubMed ID: 11659324
[No Abstract] [Full Text] [Related]
13. New rules for new drugs: the challenge of AIDS to the regulatory process.
Edgar H; Rothman DJ
Milbank Q; 1990; 68(Suppl. 1):111-42. PubMed ID: 11650413
[TBL] [Abstract][Full Text] [Related]
14. Informed consent: the FDA's perspective.
Bagley G
Food Drug Law J; 1993; 48(2):181-6. PubMed ID: 11653141
[No Abstract] [Full Text] [Related]
15. Innovative AIDS drug plan may be undermining testing.
Kolata G
N Y Times Web; 1989 Nov; ():A1, C15. PubMed ID: 11646742
[No Abstract] [Full Text] [Related]
16. U.S. permits AIDS patients to use unproved drug.
Kolata G
N Y Times Web; 1989 Jan; ():A1, B6. PubMed ID: 11646713
[No Abstract] [Full Text] [Related]
17. Into the unknown: AIDS patients test drugs.
Navarro M
N Y Times Web; 1992 Feb; ():1, 29. PubMed ID: 11646911
[No Abstract] [Full Text] [Related]
18. Stigma, conflict, and the approval of AIDS drugs.
Hansen RW; Ranelli PL; Ried LD
J Drug Issues; 1995; 25(1):129-39. PubMed ID: 11653301
[No Abstract] [Full Text] [Related]
19. A chance at life for AIDS sufferers.
Krim M
N Y Times Web; 1986 Aug; ():A27. PubMed ID: 11646177
[No Abstract] [Full Text] [Related]
20. Regulatory concerns regarding AIDS vaccine development.
Sawyer LA; Katzenstein DA; Quinnan GV
AIDS Public Policy J; 1988; 3(3):36-45. PubMed ID: 11650100
[No Abstract] [Full Text] [Related]
[Next] [New Search]
